Skip to main content

Table 5 Risk of ADRs in response to methotrexate (MTX) and glucocorticoids (GCs) based on logistic regression

From: Adverse drug reactions associated with treatment in patients with chronic rheumatic diseases in childhood: a retrospective real life review of a single center cohort

  Logistic regression to methotrexate
Variable OR Adjusted OR
(IC95%) p (IC95%) p
Sex: male (ref-female) 1.01 (0.65–1.56) 0.978 1.04 (0.61–1.77) 0.882
Age (years) 0.84 (0.80–0.88) < 0.001
Age ≤ 16 years (ref-more than 16 years) 9.45 (5.15–17.31) < 0.001 9.68 (4.86–19.28) < 0.001
Administration routes of methotrexate (ref-oral)
 Subcutaneous 1.92 (1.07–3.44) 0.028 2.10 (1.05–4.20) 0.036
Dose 5.14 (2.14–12.36) < 0.001 1.21 (0.4–3.68) 0.737
Dose of methotrexate ≥ 0.6 mg/kg/week (ref-more than 0,6) 2.09 (1.37–3.19) 0.001
Disease (ref.- JIA)
 JSLE 0.62 (0.31–1.27) 0.195 2.4 (0.95–6.07) 0.064
 JDM 0.34 (0.19–0.61) < 0.001 0.40 (0.2–0.79) 0.008
  Logistic regression to glucocorticoid
Variable OR Adjusted OR
(IC95%) p (IC95%) p
Sex: male (ref.- female) 0.55 (0.33–0.91) 0.02 1.10 (0.50–2.38) 0.816
Age (years) 0.86 (0.81–0.91) < 0.001
Age ≤ 16 years 6.67 (3.69–12.07) < 0.001 9.92 (4.36–22.54) < 0.001
(ref.- more than 16 years)
Dose of glucocorticoid (oral) 5.63 (2,88-11,00) < 0,001
Dose of glucocorticoid (oral) ≥ 0.5 mg/kg/day (ref.-less than 0.5) 2.51 (1.59–3.95) < 0.001 1.88 (0.96–3.69) 0.067
30 mg/kg/dose (Pulse therapy) 0.26 (0.07–0.89) 0.033 0.54 (0.12–2.39) 0.42
Disease (ref.- JSLE)
 JIA 0.03 (0.02–0.06) < 0.001 0.03 (0.01–0.06) < 0.001
 JDM 0.07 (0.03–0.14) < 0.001 0.05 (0.02–0.11) < 0.001
  1. ADR - adverse drug reaction, OR - odds ratio, aOR - adjusted odd ratios, CI - confidence interval, p - probability of significance, Ref - reference, JIA - juvenile idiopathic arthritis, JSLE - juvenile systemic lupus erythematosus, JDM - juvenile dermatomyositis, MTX - methotrexate, mg/kg-milligrams per kilogram, GCs - glucocorticoids
\